REYON Pharmaceutical Co., Ltd. (KRX:102460)

Market Cap	225.96B
Revenue (ttm)	148.04B
Net Income (ttm)	4.04B
Shares Out	18.34M
EPS (ttm)	220.05
PE Ratio	55.99
Forward PE	n/a
Dividend	150.00 (1.22%)
Ex-Dividend Date	n/a

Volume	74,927
Average Volume	178,613
Open	12,030
Previous Close	11,920
Day's Range	11,840 - 12,450
52-Week Range	9,830 - 18,650
Beta	0.69
RSI	58.33
Earnings Date	Aug 14, 2025

About REYON Pharmaceutical

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1955
• Employees: 448
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 102460

Financial Performance

In 2024, REYON Pharmaceutical's revenue was 148.30 billion, a decrease of -1.83% compared to the previous year's 151.07 billion. Earnings were 4.15 billion, an increase of 15.85%.